Physician profile
Charles E Evans
NPI 1326335902
$11,841.11
in general payments reported to CMS, 2019-2025
36 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $941 · 2021: $970 · 2022: $1,619 · 2023: $1,895 · 2024: $2,198 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,541.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,860.28 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,007.18 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,117.04 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $983.93 | 2019-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $587.15 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $445.73 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $394.34 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $384.87 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $224.53 | 2022-2025 | Glassia |
| Genentech USA, INC. | $165.76 | 2019-2023 | Xolair |
| Electromed, INC. | $148.72 | 2024-2025 | Smartvest |
| Insmed, INC. | $147.93 | 2022-2025 | Arikayce, Brinsupri |
| Inari Medical, INC. | $147.79 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $143.75 | 2019-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $138.80 | 2025 | Ohtuvayre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120.57 | 2022-2025 | Zerbaxa |
| Abbvie INC. | $97.92 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $84.90 | 2019-2020 | |
| United Therapeutics Corporation | $82.45 | 2022-2025 | Tyvaso, Tyvaso |
| Gilead Sciences, INC. | $78.41 | 2019 | |
| 3b Medical, INC. | $68.97 | 2024-2025 | Luna |
| Ambu INC. | $54.01 | 2022-2025 | |
| Csl Behring | $51.76 | 2020 | |
| Amgen INC. | $44.81 | 2023-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $40.22 | 2019 | |
| Portola Pharmaceuticals, LLC | $32.08 | 2019 | |
| Viatris Specialty LLC | $27.14 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $25.20 | 2019-2020 | |
| Philips North America LLC | $24.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.23 | 2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $19.33 | 2023 | Hillrom - Life 2000 Ventilation System |
| Boston Scientific Corporation | $16.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.42 | 2022 | |
| Shire North American Group INC | $14.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.14 | 2020 | |
| Pfizer INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.